STOCK TITAN
  1. Home
  2. News
  3. ABBV

Abbvie Inc - ABBV STOCK NEWS

Welcome to our dedicated news page for Abbvie (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abbvie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abbvie's position in the market.

News
AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
Rhea-AI Summary
AbbVie and Allergan Aesthetics to Present 29 Abstracts at AAD 2024, Highlighting Efficacy and Safety Data Across Dermatology and Aesthetic Portfolios
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
conferences
-
News
JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval
Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, receives U.S. FDA approval for JUVÉDERM® VOLUMA® XC, the first hyaluronic acid dermal filler for temple hollowing. Results last up to 13 months with 80% improvement in temple hollowing. The approval addresses a significant unmet need in aesthetics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
fda approval
-
News
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
Rhea-AI Summary
Dragonfly Therapeutics announces milestone payment from AbbVie for ABBV-303 entering clinical trials for solid tumors, marking the sixth TriNKET® drug using Dragonfly's platform technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
clinical trial
News
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
Rhea-AI Summary
AbbVie Inc. and OSE Immunotherapeutics collaborate to develop OSE-230, a monoclonal antibody targeting chronic inflammation. OSE to receive $48 million upfront and up to $665 million in milestone payments. AbbVie gains exclusive global license for OSE-230.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
partnership
-
News
AbbVie to Present at the TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
AbbVie (ABBV) to participate in the TD Cowen 44th Annual Health Care Conference on March 5, 2024. Key executives to present at 8:10 a.m. Central time. Live webcast and archived session available on AbbVie's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
conferences
-
News
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
Rhea-AI Summary
Genmab A/S (GMAB) and AbbVie (ABBV) receive FDA Priority Review for epcoritamab in R/R follicular lymphoma, with a target action date of June 28, 2024. The sBLA submission is based on positive Phase 1/2 EPCORE™ NHL-1 trial results, showing promising treatment responses. Epcoritamab aims to address the unmet needs of difficult-to-treat FL patients, with potential utility across B-cell malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
clinical trial
News
U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)
Rhea-AI Summary
AbbVie's epcoritamab-bysp granted Priority Review for the treatment of relapsed or refractory follicular lymphoma, with Breakthrough Therapy Designation by the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
-
News
Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity
Rhea-AI Summary
Cosette Pharmaceuticals, Inc. receives FDA approval for the first generic version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days exclusivity. The company plans to commence commercial shipments soon, marking a significant milestone in their product portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
none
-
News
AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
Rhea-AI Summary
AbbVie Inc. and Tentarix Biotherapeutics have entered into a collaboration to develop novel biologics in oncology and immunology using Tentarix's Tentacles™ platform. AbbVie will have the exclusive option to acquire the therapeutic programs after candidate nomination by Tentarix, with upfront option payments totaling $64 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
none
News
BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs
Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, launches the 2024 BOTOX® Cosmetic grant program to support women entrepreneurs by providing funding, mentorship, coaching, and community. The program aims to address the Confidence Gap by awarding 20 women entrepreneurs with $25,000 grants to grow their businesses, as women-owned businesses face funding disparities and financial challenges.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
none
Stock ABBV logo
Abbvie Inc

NYSE:ABBV

ABBV Rankings

#28 Ranked by Market Cap
#2312 Ranked by Stock Gains
#934 Ranked by Dividends

ABBV Stock Data

287.80B
1.76B
0.11%
71.92%
0.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
North Chicago

About ABBV

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.